Peter Campbell named CSO at Quotient Therapeutics
Dr Campbell previously served as Head of Cancer, Ageing and Somatic Mutation at Sanger where his research programme focused on the genetic changes that cells acquire throughout life, and how these mutations are related to ageing, cancer and other disease processes.
His research also focused on cancer genomics, particularly genome-wide analyses of somatic mutations in tumours. Dr Campbell has received numerous accolades over the course of his career including his election to the U.S. National Academy of Medicine in 2022, in recognition for his contribution to the field of cancer genomics.
He was also awarded the Royal Society’s Darwin Medal in 2023 for his significant discoveries and major influence in the fields of cancer genomics and somatic evolution. Dr Campbell received his Ph.D. from the University of Cambridge and completed his postdoctoral fellowship at the Wellcome Sanger Institute.
He said: “The somatic genome holds tremendous untapped insights into the genetic changes that result in some of today’s most debilitating diseases.
“Quotient’s Somatic Genomics platform has the potential to identify intrinsically validated genes, proteins and pathways that can be used as targets for the development of transformative therapies in a wide range of indications.
“After devoting considerable time to helping establish the company, the opportunity to lead the scientific efforts at Quotient was irresistible. I see remarkable potential to realise the full promise of this revolutionary approach and technology to develop treatments that could cure, prevent, or reverse diseases for patients.”
Jacob Rubens, Co-Founder and CEO of Quotient Therapeutics, added: “As one of the academic co-founders of Quotient and a pioneer in somatic genetics, Peter’s expertise and scientific leadership will be invaluable as we continue to advance the first-ever Somatic Genomics platform.
“We’ve made remarkable progress in scaling the platform to date and with Peter’s scientific leadership, we’ll further accelerate our research efforts to discover disease modifying therapies.
“I look forward to working closely with him and the rest of the team as we pioneer a new field of genetics to produce first-in-class medicines across a multitude of diseases.”
Quotient was founded by Flagship Pioneering, a Cambridge Massachusetts company, in 2022. Flagship invests in biotechnology, life sciences, health and sustainability companies.